Tomas Navratil
Corporate Officer/Principal at GLAUKOS CORPORATION
Net worth: 7 M $ as of 2024-03-30
Profile
Tomas Navratil is currently the Chief Development Officer at Glaukos Corp.
He also holds a position on the Member-Supervisory Board at Severomoravske Vodovody a Kanalizace Ostrava as.
Previously, he worked as the Director-Medical & Scientific Affairs at Inspire Pharmaceuticals, Inc., the Executive Director-Clinical Research at Parion Sciences, Inc., the General Manager at Nicox Ophthalmics, Inc., the Executive VP, Global Head-Research & Development at Nicox SA, and the Senior Vice President-Development at Envisia Therapeutics, Inc. Dr. Navratil obtained his undergraduate and doctorate degrees from The University of North Carolina at Charlotte.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
GLAUKOS CORP
0.15% | 2024-03-31 | 73,674 ( 0.15% ) | 7 M $ | 2024-03-30 |
Tomas Navratil active positions
| Companies | Position | Start |
|---|---|---|
| GLAUKOS CORPORATION | Corporate Officer/Principal | 2022-03-31 |
Severomoravske Vodovody a Kanalizace Ostrava as
 Severomoravske Vodovody a Kanalizace Ostrava as Water UtilitiesUtilities Severomoravske Vodovody a Kanalizace Ostrava AS engages in the production and supply of drinking water. It also deals with the discharge and treatment of wastewater. The company was founded on April 30, 1992 and is headquartered in Ostrava, Czech Republic. | Director/Board Member | - |
Former positions of Tomas Navratil
| Companies | Position | End |
|---|---|---|
Nicox Ophthalmics, Inc.
 Nicox Ophthalmics, Inc. Pharmaceuticals: MajorHealth Technology Nicox Ophthalmics, Inc. develops ocular diseases treatment products. It offers extensive pipeline such as a number of clinical and pre-clinical programs that principally target ocular allergy, ocular inflammation, and blepharitis. The company was founded by Thomas Cavanagh on December 21, 2007 and is headquartered in Fort Worth, TX. | Corporate Officer/Principal | - |
Inspire Pharmaceuticals, Inc.
 Inspire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Inspire Pharmaceuticals, Inc. operated as a biopharmaceutical company. It discovered and developed pharmaceutical products to treat diseases that results from deficiencies in the body's natural mechanisms of mucosal hydration. The company was founded by Kendall Harden, Richard C. Boucher, Andre L. Lamotte, H. Jefferson Leighton and Terrance G. McGuire and was headquartered in Whitehouse Station, NJ. | Chief Tech/Sci/R&D Officer | - |
| NICOX SA | Chief Tech/Sci/R&D Officer | - |
Parion Sciences, Inc.
 Parion Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Parion Sciences operates as a development-stage pharmaceutical company focused on the discovery and development of new treatments for serious diseases in multiple therapeutic areas. The firm's technology corrects defects in the innate defense of mucosal surfaces by developing inhibitors of the epithelial sodium channel (ENaC). The company was founded by Richard C. Boucher and is headquartered in Durham, NC. | Corporate Officer/Principal | - |
Envisia Therapeutics, Inc.
 Envisia Therapeutics, Inc. BiotechnologyHealth Technology Envisia Therapeutics, Inc. develops novel ocular therapies. It provides glaucoma drug therapies that include PRINT particle therapeutics to overcome biologic and chemical. The company was founded by 2013 is headquartered in Morrisville, NC. | Corporate Officer/Principal | - |
Training of Tomas Navratil
| The University of North Carolina at Charlotte | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| GLAUKOS CORPORATION | Health Technology |
| NICOX SA | Health Technology |
| Private companies | 5 |
|---|---|
Inspire Pharmaceuticals, Inc.
Inspire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Inspire Pharmaceuticals, Inc. operated as a biopharmaceutical company. It discovered and developed pharmaceutical products to treat diseases that results from deficiencies in the body's natural mechanisms of mucosal hydration. The company was founded by Kendall Harden, Richard C. Boucher, Andre L. Lamotte, H. Jefferson Leighton and Terrance G. McGuire and was headquartered in Whitehouse Station, NJ. | Health Technology |
Parion Sciences, Inc.
Parion Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Parion Sciences operates as a development-stage pharmaceutical company focused on the discovery and development of new treatments for serious diseases in multiple therapeutic areas. The firm's technology corrects defects in the innate defense of mucosal surfaces by developing inhibitors of the epithelial sodium channel (ENaC). The company was founded by Richard C. Boucher and is headquartered in Durham, NC. | Commercial Services |
Nicox Ophthalmics, Inc.
Nicox Ophthalmics, Inc. Pharmaceuticals: MajorHealth Technology Nicox Ophthalmics, Inc. develops ocular diseases treatment products. It offers extensive pipeline such as a number of clinical and pre-clinical programs that principally target ocular allergy, ocular inflammation, and blepharitis. The company was founded by Thomas Cavanagh on December 21, 2007 and is headquartered in Fort Worth, TX. | Health Technology |
Severomoravske Vodovody a Kanalizace Ostrava as
Severomoravske Vodovody a Kanalizace Ostrava as Water UtilitiesUtilities Severomoravske Vodovody a Kanalizace Ostrava AS engages in the production and supply of drinking water. It also deals with the discharge and treatment of wastewater. The company was founded on April 30, 1992 and is headquartered in Ostrava, Czech Republic. | Utilities |
Envisia Therapeutics, Inc.
Envisia Therapeutics, Inc. BiotechnologyHealth Technology Envisia Therapeutics, Inc. develops novel ocular therapies. It provides glaucoma drug therapies that include PRINT particle therapeutics to overcome biologic and chemical. The company was founded by 2013 is headquartered in Morrisville, NC. | Health Technology |
- Stock Market
- Insiders
- Tomas Navratil
